Phase 3 PROSERA Topline Results February 2026 Forward Looking Statements This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strategy, prospective products, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, and future results of c ...

Core Viewpoint - Gossamer Bio Inc. (NASDAQ:GOSS) is highlighted as a promising multibagger stock, primarily due to its lead asset, Seralutinib, which targets pulmonary arterial hypertension (PAH) [1] Group 1: Stock Performance - The stock has seen significant growth, rising from approximately $1 at the beginning of the year to $2.50, resulting in nearly 180% returns year-to-date [1] - Analyst sentiment has strengthened, with a Buy rating from Piper Sandler and a price target of $15 reiterated [2] - H.C. Wainwright also reaffirmed a Buy rating with a target of $10, indicating confidence in Seralutinib [3] Group 2: Drug Development and Trials - Recent literature reviews and trial extensions have bolstered optimism around Seralutinib, with Phase 2 study data showing benefits sustained for 72 weeks, including reduced pulmonary vascular resistance and improved six-minute walk distance [4] - The potential for Seralutinib to be used in combination with other therapies could expand its application in pulmonary treatment [5] - The upcoming Phase 3 PROSERA trial, with results expected in February 2026, is identified as a significant upcoming catalyst for the company [5] Group 3: Company Overview - Gossamer Bio Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for pulmonary and cardiovascular diseases [5]